Meeting
2023 ASCO Annual Meeting
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
Authors
Yelena Y. Janjigian
Memorial Sloan Kettering Cancer Center, New York, NY
Yelena Y. Janjigian , Kohei Shitara , Markus H. Moehler , Marcelo Garrido , Carlos Gallardo , Lin Shen , Kensei Yamaguchi , Lucjan Wyrwicz , Tomasz Skoczylas , Arinilda Silva Campos Bragagnoli , Tianshu Liu , Mustapha Tehfe , Elena Elimova , Ricardo Elias Bruges Maya , James M. Cleary , Michalis Karamouzis , Samira Soleymani , Ming Lei , Carlos Amaya-Chanaga , Jaffer A. Ajani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02872116
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4025)
DOI
10.1200/JCO.2023.41.16_suppl.4025
Abstract #
4025
Poster Bd #
347
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up.
First Author: Lin Shen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.
First Author: Lin Shen
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC).
First Author: Ryan Sugarman